The US Food and Drug Administration has approved Akebia Therapeutics’ drug vadadustat for the treatment of anaemia caused by chronic kidney disease (CKD) in patients on dialysis, the drug maker said on Wednesday. The drug will be available under the brand name Vafseo, the company added.